Prognostic value of pro-inflammatory markers at the preoperative stage in Algerian women with breast cancer

Figures & Tables

Characteristic		Untreated BC
Age Median (range)		46 (30–75)
T stage	T1	8 (13.55%)
	T2	30 (50.84%)
	T3	8 (13.55%)
	T4	8 (13.55%)
	ND	5 (8.47%)

N stage	N0	20 (33.89%)
	N1	28 (47.45%)
	N2	5 (8.47%)
	N3	1 (1.69%)
	ND	5 (8.47%)

Stage disease	IA	2 (3.39%)
	IIA	21 (35.59%)
	IIB	17 (28.81%)
	IIIA	6 (10.17%)
	IIIB	8 (13.55%)
	IIIC	1 (1.69%)
	ND	4 (6.78%)

Laterality of tumor	Right breast	24 (40.67%)
Laterality of tumor	Left breast	35 (59.32%)

Histological classification	CCI	49 (83.05%)
	CLI	4 (6.78%)
	Mixte	5 (8.47%)
	colloid	1 (1.69%)

SBR classification	I	1 (1.69%)
	II	35 (59.32%)
	II/III	2 (3.39%)
	III	20 (33.89%)
	ND	1 (1.69%)

Molecular classification	Lum A	6 (10.17%)
	Lum B	24 (40.67%)
	Lum B-like	7 (11.86%)
	HER2+	9 (15.25%)
	TNBC	8 (13.55%)
	Lum A or B	5 (8.47%)

Treatment	Chemotherapy	58/59
	Radiotherapy	51/59
	Hormonotherapy	36/42
	Anti-HER2	16/16

Subgroups	N	SII		P value	N	NLR		P value	N	MLR		P value	N	SIRI		P value

		Low	High			Low	High			Low	High			Low	High
Recurrence-free survival
Age	59			0.601	59			0.7787	42			0.3357	42			0.3357
≤ 46		14	16			20	10			6	16			6	16
> 46		11	18			21	8			9	11			9	11
T staging	55			0.5648	55			0.2127	39			1	39			0.7281
T1+T2		16	23			29	10			10	16			11	15
T3+T4		8	8			9	7			5	8			4	9
N staging	55			1	55			0.7630	39			1	39			1
N0		9	11			13	7			4	7			4	7
N+		15	20			25	10			11	17			10	18
Clinical staging	55			1	55			0.1892	39			1	39			0.7281
I+II		17	23			30	10			10	16			11	15
III+IV		7	8			8	7			5	8			4	9
SBR classification	58			0.2661	58			1	41			1	41			0.1703
I+II		18	20			26	12			9	18			7	20
III		6	14			13	7			5	9			7	7
Laterality of tumor	59			0.7897	59			1	42			0.2072	42			1
Right breast		11	13			16	8			4	13			6	11
Left breast		14	21			24	11			11	14			9	16
Distant metastasis-free survival
Age	59			0.601	59			1	42			1	42			0.3357
≤ 46		14	16			8	22			17	5			6	16
> 46		11	18			8	21			16	4			9	11
T staging	55			0.5648	55			0.3263	39			0.1938	39			0.7281
T1+T2		16	23			9	30			23	3			11	15
T3+T4		8	8			6	10			9	4			4	9
N staging	55			1	55			0.5308	39			1	39			1
N0		9	11			4	16			9	2			4	7
N+		15	20			11	24			23	5			10	18
Clinical staging	55			1	55			0.7348	39			0.1938	39			0.7281
I+II		17	23			10	30			23	3			11	15
III+IV		7	8			5	10			9	4			4	9
SBR classification	58			0.2661	58			0.5413	41			0.6925	41			0.1703
I+II		18	20			11	27			20	7			7	20
III		6	14			4	16			12	2			7	7
Laterality of tumor	59			0.7897	59			0.1518	42			0.2708	42			1
Right breast		11	13			9	15			15	2			6	11
Left breast		14	21			7	28			18	7			9	16

Subgroups	Cutoff value	AUC	Sensitivity (%)	Specificity (%)	Youden index	95% CI of AUC	P-value
Recurrence-free survival
NLR	2.11	0.568	41.4	76.7	0.181	0.425–0.712	0.35
PLR	291.81	0.440	6.9	100	0.069	0.295–0.585	0.419
SII	472	0.578	69	53.3	0.223	0.434–0.722	0.287
MLR‡	0.16	0.693	85.7	57.1	0.428	0.538–0.847	0.014
SIRI‡	0.6888	0.741	85.7	57.1	0.428	0.598–0.885	0.001
Distant metastasis-free survival
NLR	1.6	0.59	88.9	34.1	0.23	0.434–0.746	0.258
PLR	128.33	0.497	50	63.4	0.134	0.334–0.660	0.974
SII	472	0.634	77.8	51.2	0.29	0.49–0.779	0.069
MLR‡	0.28	0.657	41.7	86.7	0.284	0.485–0.829	0.074
SIRI‡	0.6888	0.722	91.7	46.7	0.384	0.569–0.875	0.004
Overall survival
NLR	2.85	0.508	42.9	90.4	0.333	0.208–0.808	0.957
PLR	119.52	0.404	57.1	50	0.071	0.174–0.633	0.412
SII	712	0.544	42.9	80.8	0.237	0.295–0.793	0.730
MLR‡	0.11	0.559	100	18.9	0.189	0.3–0.819	0.653
SIRI‡	1.3823	0.605	40	86.5	0.265	0.346–0.865	0.426